GLP-1 Medications Show Promise in Reducing Addiction Risk, Study Finds
A new study published in The British Journal of Medicine suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (marketed as Wegovy and Ozempic), may be associated with a significant reduction in the risk of substance use disorders.
Study Details and Findings
Researchers analyzed health data from over 600,000 American veterans with type 2 diabetes to investigate the impact of GLP-1 agonists on various addictions. The study aimed to determine if initiating treatment with these medications reduced the risk of developing a substance use disorder in individuals with no prior history, and whether they could lessen complications in those already struggling with addiction.
Substances examined included alcohol, cannabis, cocaine, nicotine, and opioids, as well as other potentially addictive drugs.
The results indicated that treatment with GLP-1 receptor agonists correlated with a reduced risk of developing several substance use disorders:
- Alcohol: -18%
- Cannabis: -14%
- Cocaine: -20%
- Nicotine: -20%
- Opioids: -25%
in individuals already dependent on substances, these medications were associated with a reduction in serious events like hospitalizations, overdoses, and deaths related to addiction.
How GLP-1 Agonists Might Assist
Researchers hypothesize that the biological mechanisms of GLP-1 agonists – which affect brain circuits linked to appetite and reward – could also influence addictive behaviors. This opens a potential new therapeutic avenue for addiction treatment.
Essential Considerations
The authors emphasize that the study is observational and demonstrates a correlation, not a direct causal link. Clinical trials are necessary to confirm whether these drugs can ultimately grow a treatment for addiction.
Wegovy and Ozempic: Already Popular Medications
GLP-1 agonists like semaglutide are already widely used for weight management and diabetes treatment. Semaglutide mimics a natural hormone that regulates blood sugar and satiety, reducing appetite and promoting weight loss. Wegovy is specifically approved for weight loss, while Ozempic is approved for type 2 diabetes.
The FDA approved Wegovy as a pill in December 2025, offering a new administration option for patients.
Future Directions
If the findings of this study are confirmed through clinical trials, the scope of application for these medications could expand significantly, offering new hope in the fight against addiction alongside their existing roles in managing diabetes and obesity.